China Reassures Public On Usage Of Topical Ibuprofen
This article was originally published in PharmAsia News
Following U.S. FDA's recent warning to eight U.S. manufacturers of topical ibuprofen, China's State FDA has given its assurance that according to China's safety data, the drug does not show serious adverse reactions other than itching, flush and rash
You may also be interested in...
Chief medical officer Samit Hirawat outlines R&D successes – though there have been some setbacks since it bought Celgene for $74bn last year – and the company’s commitment to clinical trial diversity.
Letter from department’s general counsel responds to request from the company for a pre-enforcement advisory opinion. Despite the letter, Lilly maintains its ‘limited distribution program is fully consistent with applicable laws and regulations.’
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.